CD19 and lymphoma: We then performed a pilot in vivo test using immunodeficient Nod/SCID/interleukin-2 receptor (IL-2R)γNull (NSG) mice injected intravenously with human Ramos lymphoma cells stably expressing firefly luciferase (FLUC), followed by treatment on day 3 posttumor injection with a total T cell dose of 107 untransduced T cells (mock), CD19-targeted control CAR-T cells (FMC63), or 2 CD22sdCAR-T cells (1ug36 or 1ug13 constructs).